Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.36 |
| ▸ | CETP | P11597 | 3/20 | 0.33 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.33 |
| ▸ | PRKCA | P17252 | 2/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27484355 | 0.90 | LMNA (0.52) | SMN1; SMN2LMNAALDH1A1HSD17B10MEN1 | |
| SCHEMBL30501696 | 0.89 | TSHR (0.35) | MEN1KMT2ATSHRSIRT2CETP | |
| SCHEMBL25392534 | 0.89 | TSHR (0.35) | MEN1KMT2ATSHRSIRT2CETP | |
| SCHEMBL30501669 | 0.89 | TSHR (0.35) | MEN1KMT2ATSHRSIRT2CETP | |
| SCHEMBL25390367 | 0.89 | TSHR (0.35) | MEN1KMT2ATSHRSIRT2CETP | |
| SCHEMBL25392376 | 0.89 | TSHR (0.35) | MEN1KMT2ATSHRSIRT2CETP | |
| SCHEMBL25392277 | 0.89 | TSHR (0.35) | MEN1KMT2ATSHRSIRT2CETP | |
| SCHEMBL5712582 | 0.89 | TSHR (0.35) | MEN1KMT2ATSHRSIRT2CETP | |
| Phosphine SCHEMBL28085949 | 0.88 | LMNA (0.50) | SMN1; SMN2LMNAALDH1A1HSD17B10MEN1 | |
| SCHEMBL23533453 | 0.87 | LMNA (0.46) | SMN1; SMN2LMNAALDH1A1HSD17B10MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2528907-A1 | THERAPEUTICALLY ACTIVE CYCLOPENTANES | Allergan, Inc. (US) | 2012-12-05 | — | — | EP | disclosed |
| US-8299068-B2 | Therapeutically active cyclopentanes | ALLERGAN, INC. (US) | 2012-10-30 | — | — | US | disclosed |
| US-8299068-B2 | Therapeutically active cyclopentanes | ALLERGAN, INC. (US) | 2012-10-30 | — | — | US | disclosed |
| US-8299068-B2 | Therapeutically active cyclopentanes | ALLERGAN, INC. (US) | 2012-10-30 | — | — | US | disclosed |
| WO-2011094225-A1 | THERAPEUTICALLY ACTIVE CYCLOPENTANES | ALLERGAN, INC. (US) | 2011-08-04 | — | — | WO | disclosed |
| WO-2011094225-A1 | THERAPEUTICALLY ACTIVE CYCLOPENTANES | ALLERGAN, INC. (US) | 2011-08-04 | — | — | WO | disclosed |
| US-20110190286-A1 | THERAPEUTICALLY ACTIVE CYCLOPENTANES | ALLERGAN, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| US-20110190286-A1 | THERAPEUTICALLY ACTIVE CYCLOPENTANES | ALLERGAN, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| US-20110190286-A1 | THERAPEUTICALLY ACTIVE CYCLOPENTANES | ALLERGAN, INC. (US) | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190286-A1 | THERAPEUTICALLY ACTIVE CYCLOPENTANES | TUBB6, ANXA5, TUBB1 | SMN1; SMN2 2479/4885LMNA 2767/4885ALDH1A1 898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.